글로벌 리소좀 산성 리파아제 결핍증(LAL-D) 시장 - 2030년까지의 산업 동향 및 예측

리소좀 산성 리파아제 결핍증(LAL-D) 시장 분석 및 규모

리소좀 산성 리파아제 결핍증(LAL-D)은 울만병 또는 콜레스테릴 에스테르 저장병(CESD)으로도 알려져 있으며, 리소좀 산성 리파아제 효소 결핍을 특징으로 하는 희귀 유전 질환입니다. 이 효소는 신체의 지방과 콜레스테롤을 분해하는 데 중요한 역할을 합니다. 결핍되거나 기능이 없으면 다양한 조직과 장기에 지질(지방)이 축적되어 광범위한 증상과 건강 합병증을 유발합니다. 진단 도구와 유전자 검사 의 발전으로 LAL-D 사례를 식별하고 확인하는 것이 더 쉬워졌습니다. 조기에 정확한 진단을 내리는 것이 이 질환을 효과적으로 관리하는 데 중요합니다. 수년에 걸쳐 의료 전문가, 환자 및 일반 대중 사이에서 LAL-D와 같은 희귀 질환에 대한 인식이 크게 증가했습니다. 이러한 인식 향상으로 인해 이 질환에 대한 보다 정확한 진단과 치료가 이루어졌습니다.

Data Bridge Market Research는 2022년에 6억 1,200만 달러였던 (LAL-D) 시장이 2030년까지 1,3억 1,188만 달러에 도달할 것으로 예상되며 예측 기간 동안 10.0%의 CAGR을 경험할 것으로 분석했습니다. 이는 시장 가치를 나타냅니다. "조기 발병 울만병"은 후기 단계 실패와 치료제 개발 부문에 도움이 되는 전임상 스크리닝 활동에 투자하는 제약 및 생물 제약 회사의 증가로 인해 리소좀 산성 리파아제 결핍증(LAL-D) 시장의 유형 세그먼트를 지배합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

리소좀 산성 리파제 결핍증(LAL-D) 시장 범위 및 세분화

Market Definition

Lysosomal acid lipase deficiency (LAL-D) market is the commercial and healthcare ecosystem related to the diagnosis, treatment, and management of lysosomal acid lipase deficiency, also known as wolman disease or cholesteryl ester storage disease (CESD). LAL-D is a rare genetic disorder characterized by a deficiency of the lysosomal acid lipase enzyme, which plays a crucial role in breaking down fats and cholesterol in the body. When this enzyme is deficient or nonfunctional, it leads to the accumulation of lipids (fats) in various tissues and organs, causing a wide range of symptoms and health complications.

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Dynamics

Drivers

• Advancements in Diagnostic Technologies

Advances in diagnostic tools and genetic testing have made it easier to diagnose LAL-D. More accurate and accessible diagnostic methods enable earlier identification of affected individuals, which is crucial for timely intervention.

• Patient Advocacy and Support

Patient advocacy groups and foundations dedicated to LAL-D raise awareness, provide support to affected individuals and their families, and actively promote research. Their efforts help drive interest and investment in finding effective treatments.

Opportunity

• Evolving Healthcare Landscape

Changes in healthcare systems, such as an increased focus on rare diseases, personalized medicine, and precision diagnostics, contribute to the growth of the LAL-D market. Healthcare providers are better equipped to diagnose and manage rare diseases such as LAL-D.

Moreover, the demand for lysosomal acid lipase deficiency (LAL-D) is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the lysosomal acid lipase deficiency (LAL-D) market in the above mentioned projected timeframe.

Restraint/Challenge

• Long Development Timelines

Developing treatments for rare diseases often involves lengthy research and development timelines, including clinical trial phases. This can delay the availability of therapies for patients who urgently need them.

Recent Developments

• Currently, Alexion Pharma’s Kanuma is the only product approved for LAL-D treatment. Kanuma (sebelipase alfa) is a subcutaneously delivered enzyme replacement treatment(ERT) approved in the EU (September 2015), U.S. (December 2015), and Japan (March 2016) for LAL-D patients
• In addition, the CESD cohort is prescribed statins and other nutritional supplements. Pfizer (Lipitor) and Merck (Zetia) are key players in the statins segment of the CSED market. However, these companies are poised to lose market share on account of significant competition from generics and approval of ERT for both early and late-onset types of this disease.  Unmet needs within the LAL-D space present a strong opportunity to develop novel first-in-class therapies

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Scope

The lysosomal acid lipase deficiency (LAL-D) market is segmented on the basis of type, treatment, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Early Onset Wolman Disease
• Late onset CESD

Treatment

• Enzyme Replacement Therapy
• Lipid-Modifying Agents (Statins)
• Surgery
• Stem Cell Transplantation
• Supportive Care

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Clinics
• Hospitals
• Ambulatory Surgical Centre
• Others

Distribution Channel

• Direct Tender
• Retail Pharmacy
• Hospital Pharmacy
• Others

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Regional Analysis/Insights

The lysosomal acid lipase deficiency (LAL-D) market is analysed and market size insights and trends are provided by type, treatment, route of administration, end-users, and distribution channel as mentioned above.

The countries covered in the lysosomal acid lipase deficiency (LAL-D) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

North America is expected to dominate the lysosomal acid lipase deficiency (LAL-D) market due to rise in the presence of key players and increased funding from public and private entities have augmented drug discovery and development and rise in the volume of expenditure carried out for advancing the technologies available for development of pharmaceuticals in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to rise in the availability of numerous advanced technologies utilized for protein binding in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The lysosomal acid lipase deficiency (LAL-D) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lysosomal acid lipase deficiency (LAL-D) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lysosomal acid lipase deficiency (LAL-D) market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Lysosomal Acid Lipase Deficiency (LAL-D) market Share Analysis

리소좀 산성 리파아제 결핍증(LAL-D) 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 리소좀 산성 리파아제 결핍증(LAL-D) 시장과 관련된 회사의 초점에만 관련됩니다.

리소좀 산성 리파아제 결핍증(LAL-D) 시장에서 활동하는 주요 업체는 다음과 같습니다.

• Alexion Pharmaceuticals, Inc. (미국)
• 파이저 주식회사(미국)
• 모레펜(인도)
• 루핀(인도)
• Triveni Interchem Private Limited(인도)
• 라넷(미국)
• Hetero Healthcare Limited(인도)
• Sun Pharmaceutical Industries Ltd.(인도)
• 지두스 카딜라(인도)
• Sandoz International GmbH(독일)
• BioCrick BioTech(중국)
• Actiza Pharmaceutical Private Limited(인도)
• Teva Pharmaceuticals USA, Inc. (미국)
• Glenmark Pharmaceutical Inc. (인도)
• ANGLE BIO PHARMA(인도)
• Accord Healthcare Limited(인도)
• 아스트라제네카(영국)
• Prudence Pharma Chem(인도)
• 노바도즈제약(미국)
• Merck & Co., Inc. (미국)의 자회사인 Merck Sharp & Dohme Corp.
• Perrigo Company plc (아일랜드)

SKU-60215